Skip to main content
AKAN
NASDAQ Life Sciences

Akanda Corp. Closes Highly Dilutive $7.0M Convertible Note Offering

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.45
Mkt Cap
$3.019M
52W Low
$1.19
52W High
$46.45
52W Position info
22% above low
Off High info
97% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

AKAN sits 22% above its 52-week low of $1.19.

Summary

Akanda Corp. has finalized its $7.0 million convertible note offering, securing capital but confirming significant dilution for existing shareholders.


Key Events · Financing and Capital Events · AKAN

  • Offering Closed

    Akanda Corp. announced the closing of its previously announced $7.0 million convertible promissory note offering to institutional investors.

  • Highly Dilutive Financing

    This offering, first announced on January 20, 2026, represents a substantial capital raise relative to the company's market valuation, indicating significant dilution for current shareholders.

  • Proceeds Allocation

    The $7.0 million in proceeds will be used for marketing ($2.3 million), working capital and general corporate purposes ($2.6 million), and debt repayment ($2.1 million).


Analysis · AKAN · Life Sciences

This filing confirms the closing of the $7.0 million convertible promissory note offering, which was previously announced on January 20, 2026. The offering is highly dilutive given the company's current market capitalization. While securing capital provides short-term liquidity, the terms of convertible notes often lead to substantial shareholder dilution. The proceeds will be allocated to marketing, working capital, and debt repayment, indicating a need for operational funding and balance sheet management.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKAN was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $1.19 to $46.45. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKAN - Latest Insights

AKAN
Sep 09, 2026, 5:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.32
Real-time Price: $3.02 info
Change: -$0.300 (-9%) info
Market Cap: $2.412M info
AKAN
Sep 04, 2026, 9:05 AM EDT
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $3.02 info
Change: -$1.33 (-31%) info
Market Cap: $2.412M info
AKAN
Aug 17, 2026, 4:49 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.31
Real-time Price: $3.02 info
Change: -$2.29 (-43%) info
Market Cap: $2.412M info
AKAN
Jun 18, 2026, 5:00 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $18.20
Real-time Price: $3.02 info
Change: -$15.18 (-83%) info
Market Cap: $2.412M info
AKAN
Jun 12, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $15.35
Real-time Price: $3.02 info
Change: -$12.33 (-80%) info
Market Cap: $2.412M info